Idioma:

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

BURRIS, H. A ; MOORE, M. J ; NELSON, R ; DORR, F. A ; STEPHENS, C. D ; VON HOFF, D. D ; ANDERSEN, J ; GREEN, M. R ; ROTHENBERG, M. L ; MODIANO, M. R ; CRIPPS, M. C ; PORTENOY, R. K ; STORNIOLO, A. M ; TARASSOFF, P

Journal of clinical oncology, 1997-06, Vol.15 (6), p.2403-2413 [Periódico revisado por pares]

Baltimore, MD: American Society of Clinical Oncology

Sem texto completo

Citações Citado por

Enviar para

Título:
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
Autor: BURRIS, H. A ; MOORE, M. J ; NELSON, R ; DORR, F. A ; STEPHENS, C. D ; VON HOFF, D. D ; ANDERSEN, J ; GREEN, M. R ; ROTHENBERG, M. L ; MODIANO, M. R ; CRIPPS, M. C ; PORTENOY, R. K ; STORNIOLO, A. M ; TARASSOFF, P
Assuntos: Adult ; Aged ; Antimetabolites, Antineoplastic - adverse effects ; Antimetabolites, Antineoplastic - therapeutic use ; Antineoplastic agents ; Biological and medical sciences ; Chemotherapy ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Female ; Fluorouracil - adverse effects ; Fluorouracil - therapeutic use ; Gemcitabine ; Humans ; Infusion Pumps ; Male ; Medical sciences ; Middle Aged ; Morphine - therapeutic use ; Narcotics - therapeutic use ; Pain - drug therapy ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - mortality ; Pharmacology. Drug treatments ; Survival Rate ; Treatment Outcome
É parte de: Journal of clinical oncology, 1997-06, Vol.15 (6), p.2403-2413
Descrição: Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a significant impact on the disease. In early studies with gemcitabine, patients with pancreas cancer experienced an improvement in disease-related symptoms. Based on those findings, a definitive trial was performed to assess the effectiveness of gemcitabine in patients with newly diagnosed advanced pancreas cancer. One hundred twenty-six patients with advanced symptomatic pancreas cancer completed a lead-in period to characterize and stabilize pain and were randomized to receive either gemcitabine 1,000 mg/m2 weekly x 7 followed by 1 week of rest, then weekly x 3 every 4 weeks thereafter (63 patients), or to fluorouracil (5-FU) 600 mg/m2 once weekly (63 patients). The primary efficacy measure was clinical benefit response, which was a composite of measurements of pain (analgesic consumption and pain intensity), Karnofsky performance status, and weight. Clinical benefit required a sustained (> or = 4 weeks) improvement in at least one parameter without worsening in any others. Other measures of efficacy included response rate, time to progressive disease, and survival. Clinical benefit response was experienced by 23.8% of gemcitabine-treated patients compared with 4.8% of 5-FU-treated patients (P = .0022). The median survival durations were 5.65 and 4.41 months for gemcitabine-treated and 5-FU-treated patients, respectively (P = .0025). The survival rate at 12 months was 18% for gemcitabine patients and 2% for 5-FU patients. Treatment was well tolerated. This study demonstrates that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer. Gemcitabine also confers a modest survival advantage over treatment with 5-FU.
Editor: Baltimore, MD: American Society of Clinical Oncology
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

BURRIS, H. A ; MOORE, M. J ; NELSON, R ; DORR, F. A ; STEPHENS, C. D ; VON HOFF, D. D ; ANDERSEN, J ; GREEN, M. R ; ROTHENBERG, M. L ; MODIANO, M. R ; CRIPPS, M. C ; PORTENOY, R. K ; STORNIOLO, A. M ; TARASSOFF, P

Baltimore, MD: American Society of Clinical Oncology

Buscando em bases de dados remotas. Favor aguardar.